52 research outputs found
Towards screening Barrett’s Oesophagus: current guidelines, imaging modalities and future developments
Barrett’s oesophagus is the only known precursor to oesophageal adenocarcinoma (OAC). Although guidelines on the screening and surveillance exist in Barrett’s oesophagus, the current strategies are inadequate. Oesophagogastroduodenoscopy (OGD) is the gold standard method in screening for Barrett’s oesophagus. This invasive method is expensive with associated risks negating its use as a current screening tool for Barrett’s oesophagus. This review explores current definitions, epidemiology, biomarkers, surveillance, and screening in Barrett’s oesophagus. Imaging modalities applicable to this condition are discussed, in addition to future developments. There is an urgent need for an alternative non-invasive method of screening and/or surveillance which could be highly beneficial towards reducing waiting times, alleviating patient fears and reducing future costs in current healthcare services. Vibrational spectroscopy has been shown to be promising in categorising Barrett’s oesophagus through to high-grade dysplasia (HGD) and OAC. These techniques need further validation through multicentre trials
Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies
Mo1658 - A Systematic Review and Meta-Analysis Assessing Prevalence of Barrett's Esophagus (BE) Based on Risk Factors: Implications for Screening
Mo1152 Factors Associated With Low Colorectal Screening in Minority and Ethnically Diverse Populations: A National Study in Palestine
Su2032 Irritable Bowel Syndrome in the West Bank, Palestine: Its Prevalence and Affect of Location of Residence
Mo1927 Complete Remission of Intestinal Metaplasia After One Radiofrequency Ablation Session
Su1219 BRAF Mutation Distinguishes Serrated Polyps From Tubular Adenomas: A Case Control Study
Sa1828 Comparison of Endotherapies for the Treatment of Barrett's Dysplasia and Neoplasia: What Are the Ideal Modalities?
W1102 Anti-TNF Therapy for Crohn's Disease: Predictors of Dose Escalation and Early Discontinuation By 1 Year of Therapy
- …